Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TNC shRNA2 lentivirus
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intracranial, Intratumoral
01
Overview
TNC shRNA2 lentivirus is a research-grade gene therapy tool designed to silence the expression of Tenascin-C (TNC), a hexameric glycoprotein of the extracellular matrix that is highly expressed in the tumor microenvironment of glioblastoma (GBM). The agent utilizes a lentiviral vector to deliver a specific short hairpin RNA (shRNA) sequence (designated as shRNA2) into target cells, where it triggers the RNA interference (RNAi) pathway to degrade TNC mRNA. In preclinical models of glioblastoma, TNC knockdown via this lentivirus has been shown to modulate the "go-or-grow" phenotypic switch, leading to decreased tumor invasion but potentially increased proliferation, while also altering the behavior of stromal cells like microglia and endothelial cells.
- Other names
- TNC-shRNA2 lentiviral vectorTNC-shRNA-2 lentiviral vectorTNC-shRNA 2 lentiviral vectorlentiviral TNC shRNA
02
Targets
TNC (Tenascin-C fibronectin type III domains)
Beyond the preview
Go deeper on TNC shRNA2 lentivirus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TNC shRNA2 lentivirus.